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LETTERS TO THE EDITOR
Serum a-Fetoprotein
Levels Predict Early
Virologic Response in
HIV-Positive Subjects
Treated for Chronic
Hepatitis C
To the Editor:
Seruma-fetoprotein (AFP) is a fetal
glycoprotein produced by the yolk sac
and fetal liver1 that is routinely used as
a marker of hepatocellular carcinoma
in subjects with chronic liver diseases.2,3
Elevations of AFP levels may be often
observed in acute and chronic viral hepa-
titis also4,5 and are usually associated with
hepatic cirrhosis.5,6 These elevations have
been correlated to hepatic damage per se
with selective transcriptional activation
of the AFP gene.7 Recently, it has been
demonstrated that elevated AFP levels
correlate with a low probability of sus-
tained virologic response (SVR) to
chronic hepatitis C treatment, at least in
patientswith hepatitis C virus (HCV) geno-
type 4.8 To date, no study has evaluated
the association between serum AFP levels
and early virologic response (EVR) to
anti-HCV treatment in the HIV-positive
population.
In this study we evaluated 33 con-
secutive HIV/HCV-coinfected subjects
followed up at our clinic who initiated
an anti-HCV treatment, from January
2006, with pegylated interferon a-2a (at
a dosage of 180 mg/weekly) plus ribavi-
rin (at a dosage of 1000 to 1200 mg
according to body weight) to treat HCV
infection. The aim of the present analysis
is to define the predictive role of AFP on
EVR and on rapid virologic response
(RVR) to anti-HCV treatment, which are
both strong predictors of SVR.9,10 The
following variables were collected at base-
line (time of starting anti-HCV treatment):
gender, age, race, body mass index
(BMI), platelet count, aspartate amino-
transferase (AST), alanine aminotrans-
ferase (ALT), AFP, CD4 cell counts, HIV
RNA, HCV RNA, HCV genotype, and
use of highly active antiretroviral therapy
(defined as use of $2 nucleoside reverse
transcriptase inhibitors with any protease
inhibitors or nonnucleoside reverse tran-
scriptase inhibitors). Exclusion criteria
were any other cause of liver disease
(such as hepatitis B infection), alcohol
consumption >50 g/day for men and >40
g/day for women, and contraindications
to initiation of pegylated interferon or
ribavirin treatment (psychiatric disor-
ders, anemia, cardiovascular diseases,
diabetes, or autoimmune diseases). Nor-
mal values of AFP were considered those
<4.6 IU/mL. HIV RNA load was as-
sessed using a reverse transcriptase poly-
merase chain reaction (RT-PCR) assay
with a detection limit of <60 copies/mL
(Qiagen, Heiden, Germany). Serum HCV
RNA was evaluated by nested PCR
(Amplicor; Roche, Basel, Switzerland;
detection limit <15 IU/L). HCV geno-
typing was performed using a line-probe
assay (INNO-LiPA HCV II; Immunoge-
netics, Antwerp, Belgium). Liver fibrosis
at baseline was evaluated using the FIB-4
index, which has been validated in the
HIV population.11 The index is based on
this simple equation: age ([years] 3 AST
[IU/L])/(platelets [109/L]) 3 (ALT [IU/L])1/2.
FIB-4 values >3.25 were those consid-
ered associated with advanced fibrosis.
EVR was defined as HCV RNA <15
IU/mL after 3 months of anti-HCV
treatment; RVR was defined as HCV
RNA <15 IU/L after 1 month of anti-
HCV treatment. Differences between
variables were calculated using the x2
and the Student t tests when appropriate.
Table 1 shows the demographics
and clinical characteristics of the subjects
included in our study, grouped accord-
ing to the AFP values at baseline. All
patients were white. Seventeen subjects
(51.5%) had AFP #4.6 IU/mL, and 16
(48.5%) had values >4.6 IU/mL. No
statistically significant differences were
observed in the 2 groups at baseline
according to the variables considered.
AFP >4.6 IU/mL was associated with
advanced liver fibrosis; in particular,
FIB-4 values >3.25 were observed in 4
of 17 (23.5%) subjects with AFP #4.6
IU/mL and in 8 of 16 (50%) of those with
AFP levels >4.6 IU/mL (P = 0.01). After
3 months of anti-HCV treatment, median
AST and ALT levels decreased in both
groups. In subjects with AFP #4.6 IU/
mL, median ASTandALT decreased from
101 IU/L (interquartile range [IQR]: 89
to 115) to 37 IU/L (IQR: 30 to 43;
P < 0.01) and from 93 IU/L (IQR: 63
to 101) to 35 IU/L (IQR: 29 to 46;
P < 0.01), whereas in subjects with AFP
>4.6 IU/mL median AST and ALT
decreased from 116 IU/L(IQR: 99 to
188) to 54 IU/L (IQR: 33 to 68; P < 0.01)
and from 104 IU/L (IQR: 76 to 124) to
52 IU/L (IQR: 31 to 63; P < 0.01),
respectively. RVR was achieved in 8 of
17 subjects (47.1%) with AFP #4.6 IU/
mL and in 3 of 16 (18.8%) with AFP
>4.6 IU/mL at baseline (P < 0.01); EVR
was observed in 13 of 17 subjects
(76.5%) with AFP #4.6 IU/mL and in
5 of 16 (31.3%) with AFP >4.6 IU/mL at
baseline (P < 0.001). Among the 4
subjects with AFP #4.6 IU/mL who did
not achieve EVR, 2 had genotype 1, 1
had genotype 3a, and 1 had genotype 4c/
4d. EVR was not reached by 11 subjects
with AFP >4.6 IU/mL; among these,
5 had genotype 1, 4 had genotype 3a,
and 2 had genotype 4c/4d.
To our knowledge, this is the
first study demonstrating that elevated
serum levels of AFP may be predictive of
poor rapid and early virologic response
to anti-HCV treatment in the HIV-
infected population. Our study, which
included subjects with different HCV-
genotypes, confirmed the results of
Males et al,8 who described the correla-
tion between higher AFP levels and viro-
logic response to anti-HCV treatment in
HCV-infected subjects with genotype 4.
In our study, the only factor associated
with an elevated AFP level was advanced
liver fibrosis, evaluated with the FIB-4
index because liver biopsy was not sys-
tematically performed in our cohort.11
We confirmed that recently published
findings that describe a correlation be-
tween elevated AFP levels and liver
fibrosis in HCV-infected, HIV-negative
subjects also apply to the HIV-infected
population.8,12
The identification of biochemical
markers that may predict early virologic
response to anti-HCV treatment is a very
important tool for the correct manage-
ment of the condition. Our findings sug-
gest that pretreatment levels of AFP
should be included in the routine assess-
ment of factors potentially predictive
of the anti-HCV treatment outcome. A
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prolonged follow-up is required to con-
firm the predictive role of AFP levels at
baseline in determining sustained viro-
logic response to anti-HCV treatment.
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TABLE 1. Demographics and Clinical Characteristics of the 33 HIV/HCV-Coinfected Subjects, Grouped According to Their Serum
a-Fetoprotein (AFP) Values at Baseline
AFP #4.6 (n = 17) AFP >4.6 (n = 16) Total (N = 33)
Males (%) 13 (76.5) 13 (81.2) 26 (78.8)
Median age, y (IQR) 42 (39 to 46) 43 (40 to 46) 43 (39 to 46)
BMI, kg/m2 (IQR) 22.7 (21.5 to 24.2) 23.2 (22.5 to 27.0) 23.1 (22.3 to 27.0)
CD4, cells/mm3 (IQR) 450 (352 to 570) 416 (362 to 462) 428 (356 to 546)
HIV RNA <60 copies/mL (%) 12 (70.6) 13 (81.2) 25 (75.7)
Use of HAART (%) 14 (82.3) 12 (75) 26 (78.8)
Median HCV RNA log10 copies/mL (IQR) 5.79 (5.53 to 6.27) 5.87 (5.80 to 5.94) 5.84 (5.53 to 6.27)
Median AST, IU/L (IQR) 101 (89 to 115) 116 (99 to 188) 106 (92 to 139)
Median ALT, IU/L (IQR) 93 (63 to 101) 104 (76 to 124) 97 (69 to 109)
Platelets, cells/mm3 (IQR) 214 (151 to 228) 179 (128 to 230) 197 (129 to 230)
Median total cholesterol, mg/dL (IQR) 179 (161 to 194) 152 (139 to 173) 173 (141 to 188)
Median triglycerides, mg/dL (IQR) 150 (117 to 202) 132 (96 to 172) 147 (104 to 193)
Median FIB-4 (IQR) 2.06 (1.54 to 3.23) 3.13 (2.50 to 5.21) 2.46 (1.61 to 3.89)
Genotype 1 (%) 7 (41.2) 6 (37.5) 13 (39.4)
Genotype 3 (%) 7 (41.2) 7 (43.7) 14 (42.4)
Genotype 4 (%) 3 (17.6) 3 (18.7) 6 (18.2)
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